Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2006-10-11
2010-06-29
Wehbe, Anne Marie S (Department: 1633)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C514S04400A, C435S320100
Reexamination Certificate
active
07744899
ABSTRACT:
Recombinant herpes simplex viruses comprising DNA encoding cytokines and methods for treating neoplastic diseases using the inventive recombinant viruses are disclosed.
REFERENCES:
patent: 4859587 (1989-08-01), Roizman
patent: 5231012 (1993-07-01), Mosmann et al.
patent: 5328688 (1994-07-01), Roizman
patent: 5328989 (1994-07-01), Vellekamp et al.
patent: 5585096 (1996-12-01), Martuza et al.
patent: 5641651 (1997-06-01), Roizman
patent: 6140114 (2000-10-01), Klatzmann et al.
patent: 6379674 (2002-04-01), Rabkin et al.
patent: 0 302 429 (1993-07-01), None
patent: WO 94/14971 (1994-07-01), None
patent: WO 00/40734 (2000-07-01), None
Andreansky et al. (1998) Gene Therapy, vol. 5, 121-130.
Vieweg et al. (1994) Cancer Investigation, vol. 13(2), 193-201.
Orkin et al. (1995), “Report and Recommendations of the Panel to assess the NIH investment in research on gene therapy”, 1-20.
Bronte et al. (1995) J. Immunol. vol. 154, 5283-5292.
Irvine et al. (1996) J. Immunol., vol. 156, 238 245.
Vogelstein et al. (1993) Trends in Genetics, vol. 9(4), 138-141.
Restifo et al (1993) J. Immunother., vol. 14, 182-190.
Poffenberger et al. (1983) PNAS, vol. 80(9), 2690-2694.
Advani et al. (Feb. 1998) Gene Therapy vol. 5, 160-165.
Allione, et al., “Immunizing and Curative Potential of Replicating and Nonreplicating Murine Mammary Adenocarcinoma Cells Engineered with Interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, Tumor Necrosis Factor *, Granulocyte-Macrophage Colony-stimulating Factor, and *- Interferon Gene or Admixed with Conventional Adjuvants,”Cancer Research54:6022-6026 (1994).
Andreansky, et al., “The Application of Genetically Engineered Herpes Simplex Viruses to the Treatment of Experimental Brain Tumors,”Proc. Natl. Acad. Sci. USA93:11313-11318 (1996).
Andreansky, et al., “Evaluation of Genetically Engineered Herpes Simplex Viruses as Oncolytic Agents for Human Malignant Brain Tumors,”Cancer Research57:1502-1509 (1997).
Andreansky, et al., “Treatment of Intracranial Gliomas in Immunocompetent Mice Using Herpoes Simplex Viruses that Express Murine Interleukins,”Gene Therapy5:121-130 (1998).
Aoki, et al., “Expression of Murine Interleukin-7 in a Murine Glioma Cell Line Results in Reduced Tumorigenicity in vivo,”Proc. Natl. Acad. Sci.USA89:3850-3854 (1992).
Asher, et al., “Murine Tumor Cells Transduced with the Gene for Tumor Necrosis Factor-*, Evidence for Paracrine Immune Effects of Tumor Necrosis Factor against Tumors,”J. Immunology146:3227-3234 (1991).
Ausman, et al., “Studies on the Chemotherapy of Experimental Brain Tumors: Development of an Experimental Model,”Cancer Research30:2394-2400 (1970).
Beutler, et al., “Control of Cachectin (Tumor Necrosis Factor) Syntheses: Mechanisms of Endotoxin Resistance,”Science232:977-980 (1986).
Blankenstein, et al., “Tumor Suppression after Tumor Cell-targeted Tumor Necrosis Factor * Gene Transfer,”J. Exp. Med. 173:1047-1052 (1991).
Caruso, et al., “Adenovirus-mediated Interleukin-12 Gene Therapy for Metastatic Colon Carcinoma.”Proc. Natl. Acad. USA93:11302-11306 (1996).
Chambers, et al., “Comparison of Genetically Engineered Herpes Simplex Viruses for the Treatment of Brain Tumors in aScidMouse Model of Human Malignant Glioma,”Proc. Natl. Acad. Sci. USA92:1411-1415 (1995).
Cheng, et al., “In vivo Promoter Activity and Transgene Expression in Mammalian Somatic Tissues Evaluated by Using Particle Bombardment,”Proc. Natl. Acad. Sci. USA90:4455-4459 (1993).
Cho, et al., “IL-6 Undergoes Transition from in vitro Autocrine Growth Factor to in vivo Growth Inhibitor of B Lymphoma Cells,”J. Biomed. Sci. 4:201-207 (1997).
Chou, et al., “Mapping of Herpes Simplex Virus-1 Neurovirulence to *134.5, a Gene Nonessential for Growth in Culture,”Science250:1262-1266 (1990).
Chou, et al., “Differential Response of Human Cells to Deletions and Stop Codons in the *134.5 Gene of Herpes Simplex Virus,”J. Virology68:8304-8311 (1994).
Couldwell, et al., “Malignant Glioma Modulation of Immune Function: Relative Contribution of Different Soluble Factors,”J. Neuroimmunol. 33:89-96 (1991).
Devos, et al., “Molecular Cloning of Human Immune Interferon cDNA and Its Expression in Eukaryotic Cells,”Nucl. Acids Res. 10:2487-2501 (1982).
Douvdevani, et al., “Reduced Tumorigenicity of Fibrosarcomas which Constitutively Generate IL-1* Either Spontaneously or Following IL-1* Gene Transfer,”Int. J. Cancer51:822-830 (1992).
Dranoff, et al., “Activities if Granulocyte-Macrophage Colony-Stimulating Factor Revealed by Gene Transfer and Gene Knockout Studies,”Stem Cells12:173-184 (1994).
Fakhrai, et al., “Construction and Characterization of Retroviral Vectors for Interleukin-2 Gene Therapy,”J. Immunother. 20:437-448 (1997).
Fearon, et al., “Interleukin-2 Production by Tumor Cells Bypasses T Helper Function in the Generation of an Antitumor Response,”Cell60 :397-403 (1990).
Finke, et al., “Increase of Proliferation Rate and Enhancement of Antitumor Cytoxicity of Expanded Human CD3+CD56+Immunologic Effector Cells by Receptor-mediated Transfection with the Interleukin-7 Gene,”Gene Therapy5:31-39 (1998).
Golumbeck, et al., “Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4,”Science254:713-716 (1991).
Goodwin, et al., “Human Interleulcin7: Molecular Cloning and Growth Factor Activity on Human and Murine B-Lineage Cells,”Proc. Natl. Acad. Sci. USA86:302-306 (1989).
Gray, et al., “Expression of Human Immune Interferon cDNA inE. coliand Monkey Cells,”Nature, 295:503-508 (1982).
Hock, et al., “Interleukin-7 Induces CD4+T Cell Dependent Tumor Rejection,”J. Exp. Med. 174:1291-1298 (1991).
Jenkins, et al., “Herpes Simplex Virus 1 Recombinants with Noninverting Genomes Frozen in Different Isomeric Arrangements are Capable of Independent Replication,”J. Viol. 59:494-499 (1986).
Krüger-Krasagakes, et al., “Production of Cytokines by Human Melanoma Cells and Melanocyted,”Cancer Research139:155-168 (1995).
Lagunoff, et al., “The Regulation of Synthesis and Properties of the Protein Product of Open Reading Frame P of the Herpes Simplex Virus 1 Genome,”J. Virol. 69:3615-3623 (1995).
Lee, et al., “Isolation and Characterization of a Mouse Interleukin cDNA Clone that Expresses B-Cell Stimulatory Factor 1 Activities and T-cell and Mast-cell-Stimulating Activities,”Proc. Natl. Acad. Sci. USA83:2061-2065 (1986).
Lukacs, et al., Transgene-induced Production of IL-4 Alters the Development and COllagen Expression of T Helper Cell 1-type Pulmonary Granulomas,J. Immunol. 158:4478-4484 (1997).
Maeda, et al., “Cloning of Interleukin 2 mRNAs From Human Tonsils,”Biochem. Biophys. Res. Com. 115:1040-1047 (1983).
Maliszewski, et al., “Bovine GM-CSF: Molecular Cloning and Biological Activity of the Recombinant Protein,”Mol. Immunol. 25:843-850 (1988).
March, et al., “Cloning, Sequence and Expression of Two Distinct Human Interleukin-1 Complementary DNAs,”Nature315:641-647 (1985).
Markert, et al., “Reduction and Elimination of Encephalitis in an Experimental Glioma Therapy Model with Attenuated Herpes Simplex Muitants that Retain Susceptibility to Acyclovir,”Neurosurg.32:597-603 (1993).
Martuza, et al., “Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant,”Science252:854-856 (1991).
Moore, et al., “Homology of Cytokine Synthesis Inhibitory Factor (IL-10) to the Epstein-Barr Virus Gene BCRFI,”Science248:1230-1234 (1990).
Moore, et al., “Interleukin-10,”Annu. Rev. Immunol. 11:165-190 (1993).
Moriuchi, et al., “Enhanced Tumor Cell Killing in the Presence of Ganciclovir by Herpes Simplex Virus Type 1 Vector-directed Coexpression of H
Roizman Bernard
Whitley Richard J.
Marshall & Gerstein & Borun LLP
The University of Chicago
UAB Research Foundation
Wehbe Anne Marie S
LandOfFree
Recombinant herpes simplex virus useful for treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant herpes simplex virus useful for treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant herpes simplex virus useful for treating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4237220